No Data
Cidara Therapeutics' CD388: Promising Influenza Prevention Drives Buy Rating
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Guggenheim Initiates Coverage On Cidara Therapeutics With Buy Rating, Announces Price Target of $33
Guggenheim Initiates Cidara Therapeutics(CDTX.US) With Buy Rating, Announces Target Price $33
Needham Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $25
Positive Outlook for Cidara Therapeutics Amid Strategic Advancements and Financial Stability